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A b s t r a c t  
The aim of the present work was to develop and optimize gastroretentive floating system of Quetiapine 
fumarate (QF) for the effective treatment of Schizophrenia. The present study was carried out with an 
objective of preparation and in vivo evaluation of floating tablets of using QF as a model drug using 
HPMC polymers, Gelucire 43/01 and Polyox WSR 301 to improve oral bioavailability of QF floating 
tablets by increasing gastric residence time. The tablets were prepared by direct compression method. 
The effect of polymers concentration and viscosity grades of HPMC on drug release profile was 
evaluated. The result of in vitro dissolution study showed that the drug release profile could be 
sustained by increasing the concentration of HPMC K15M and Polyox WSR 301. The optimized 
formulation (F12) containing HPMC K15M and Polyox WSR301 showed 98.6% drug release at the 
end of 12h. Changing the viscosity grade of HPMC from K15M to K100M had no significant effect on 
drug release profile. The optimized formulations (F12) containing sodium bicarbonate 40mg per tablet 
showed desired buoyancy (floating lag time of about 32seconds and total floating time of >12h). 
Optimized formulation (F12) followed diffusion controlled zero order kinetics and non-fickian transport 
of the drug. FTIR and DSC studies revealed the absence of any chemical interaction between drug 
and polymers used. The best formulation (F12) was selected based on in vitro characteristics and was 
used in vivo radiographic studies by incorporating BaSO4. These studies revealed that the tablets 
remained in the stomach for 6h in fasting human volunteers and indicated that gastric retention time 
was increased by the floating principle, which was considered desirable for the absorption window 
drugs. Studies to evaluate the pharmacokinetics in vivo showed better bioavailability, area under the 
concentration–time curve, elimination rate constant and half-life than marketed product. 
Keywords: Quetiapine fumarate, Floating drug delivery system, HPMC, Polyox WSR 301, 
Radiographic studies. 
Introduction 
Oral controlled release (CR) dosage forms (DFs) have been 
developed over the past three decades due to their considerable 
therapeutic advantages such as ease of administration, patient 
compliance and flexibility in formulation. However, this approach is 
bedilled with several physiological difficulties such as inability to 
restrain and locate the controlled drug delivery system within the 
desired region of the gastrointestinal tract due to variable gastric 
emptying and motility. Furthermore, the relatively brief gastric 
emptying time in humans which normally averages 2-3h through the 
major absorption zone, i.e., stomach and upper part of the intestine 
can result in incomplete drug release from the drug delivery system 
leading to reduced efficacy of the administered dose [1].  
Therefore, control of placement of a drug delivery system (DDS) in 
a specific region of the GI tract offers advantages for a variety of 
important drugs characterized by a narrow absorption window in the 
GIT or drugs with a stability problem [2]. Development of oral 
controlled release systems has been a challenge to formulation 
scientists because of the difficulty in localizing the system in target 
areas of the gastrointestinal tract [3]. The real challenge in the 
development of an oral controlled-release drug delivery system is 
not just to sustain the drug release but also to prolong the presence 
of the dosage form within the gastrointestinal tract (GIT) until all the 
drug is completely released at the desired period of time [4]. One of 
the novel approaches in the area of oral sustained release drug 
delivery is gastro retentive drug delivery system (GRDDS) [5]. 
Gastric retention devices are designed to prolong the gastric 
residence time of oral controlled release dosage forms. Thus result 
in increased contact time for drugs that act locally, increased 
absorption of drugs that have absorption windows in upper part of 
gastrointestinal tract (GIT), and better absorption for drugs less 
soluble in the intestinal fluid [6].  Gastro retentive drug delivery 
systems (GRDDS) can be retained in the stomach and assist in 
improving the oral sustained delivery of drugs that have an 
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absorption window in a particular region of the gastrointestinal tract. 
These systems help in continuously releasing the drug before it 
reaches the absorption window, thus ensuring optimal bioavailability 
[7]. Extended-release dosage forms with prolonged residence time 
in the stomach are highly desirable for drugs with i) narrow 
absorption windows, ii) stability problems in the intestinal or colonic 
environment, iii) local action in the stomach, and iv) low solubility at 
high pH values [8]. Floating matrix tablets are designed to prolong 
the gastric residence time after oral administration at a particular site. 
It is useful for achieving controlled plasma level as well as improving 
bioavailability [9]. Quetiapine fumarate (QF) is an atypical 
psychotropic agent approved for the treatment 
of schizophrenia, bipolar disorder and along with 
an antidepressant to treat major depressive disorder [10].  Biological 
half life of QF is 6h, due to which frequent administration is required. 
To avoid the drawbacks of frequent administrations such as plasma 
level fluctuations and patient non-compliance it is desirable to have 
a controlled release dosage forms of QF. It has been reported that 
bioavailability of QF is strongly dependent on the local physiology of 
GIT. It is readily soluble in the acidic environment of the stomach and 
thus is preferentially absorbed from the upper part of GIT. In the 
alkaline environment of intestine, precipitation of the drug occurs 
decreasing its absorption. This study was conducted with an aim to 
develop gastro retentive floating tablet using different polymers like 
HPMC K100M, HPMC K15M, Gelucire 43/01 and WSR 301, 
incorporating 200mg QF into hydrophilic polymeric matrix which 
would release the drug in stomach and upper part of GIT in a 
controlled manner. The site specific absorption of QF provides a 
strong rationale for its use as a model drug for gastro retentive 
dosage form. 
 
Materials and methods 
 
 Materials 
 
SEROQUEL SR 200mg tablet was purchased from AstraZeneca, 
Bangalore. Quetiapine fumarate was received as a gift sample from 
Aurobindo Pharma Ltd, (Hyderabad, India), Hydroxy propyl methyl 
cellulose K-15M and K-100M  were obtained from Rubicon labs, 
Mumbai, India, POLYOX WSR 301 was obtained from Dow 
chemical’s, New York. Gelucire 43/01 and PVP K 30 were gifted from 
MSN Labs Ltd, Hyderabad.  All other excipients and chemicals used 
were of analytical grade. 
 
Preparation of Quetiapine Fumarate Floating Tablets  
 
The tablets were prepared by direct compression method. All the 
ingredients except Quetiapine fumarate were passed through # 80 
mesh prior to mixing. The ingredients were weighed separately and 
mixed to get a uniform polymer mixture. The drug was then mixed 
with the polymer mixture for a period of 30 minutes to ensure uniform 
mixing of the drug. These powder mixtures were lubricated with 
magnesium stearate and compressed to obtain tablets. The 
Composition of Quetiapine fumarate floating tablets were shown in 
Table 1. 
 
Buoyancy lag time determination & total floating 
time 
 
The in vitro buoyancy was determined by the floating lag time. The 
tablet was placed in a 250 ml beaker containing 0.1N HCl. The time 
required for the tablet to rise to the surface for floating was 
determined as the buoyancy lag time and further total floating time 
of all tablets was determined by visual observation [11]. 
 
In vitro dissolution studies 
 
In vitro drug release studies for the prepared immediate release 
tablets were conducted for a period of 12h using USP XXIV type-II 
(Paddle) dissolution apparatus at 37±0.5oC at 50 rpm using 900 ml 
of 0.1N HCl as dissolution medium. At predetermined interval of 
time, 5 ml of sample was withdrawn from the dissolution medium and 
replaced with fresh medium to maintain the sink condition. After 
filtration and appropriate dilution, the samples were analyzed for 
Quetiapine fumarate by UV/Visible spectrophotometer Shimadzu 
1800 at 231 nm. 
 
Kinetic modeling of drug release  
 
The dissolution profiles of all the batches were fitted to zero order, 
first order, Higuchi and Peppas equations [12,13]. 
(Equation 1-4 respectively). 
Mt = M0 + k0t (1) 
lnMt = lnM0 + k1t (2) 
Mt = M0 – kHt1/2 (3) 
Mt/Mα =Ktn (4)  
In these equations, Mt is the cumulative amount of drug released at 
any specified time (t) and M0 is the dose of the drug incorporated in 
the delivery system and Mt/Mα is a fraction of drug released at time 
(t).  k0, k1, kH and K are rate constants for zero order, first order, 
Higuchi and Korsmeyer model respectively, n is the release 
exponent. The n value is used to characterize different release 
mechanisms for cylindrical shaped matrices. 
The dissolution data were also fitted according to the well-known 
exponential Zero Order equation, which is often used to describe 
drug release behavior from polymeric systems. 
The best fit with higher correlation (r2 > 98) was found with Higuchi’s 
equation for all the formulations.  
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Table 1: Composition of Quetiapine fumarate floating tablets 
FORMU 
LATION 
CODE 
Quetiapine 
fumarate 
(mg) 
HPMC 
K15M 
(mg) 
HPMC 
K 100M 
(mg) 
WSR 
301 
(mg) 
GELUCIRE 
43/01 
(mg) 
PVP K30 
(mg) 
NAHCO3 
(mg) 
MCC 
(mg) 
TALC 
(mg) 
Mg Stearate 
(mg) 
F1 230.4 - 75 20  10.6 30 10 2 2 
F2 230.4 - 80 25 - 10.6 35 15 2 2 
F3 230.4 - 85 25 - 10.6 40 15 2 2 
F4 230.4 40 35 20 - 10.6 30 10 2 2 
F5 230.4 40 40 25 - 10.6 35 15 2 2 
F6 230.4 45 45 30 - 10.6 40 15 2 2 
F7 230.4 - 80 15 15 10.6 30 15 2 2 
F8 230.4 60 --- 20 20 10.6 35 20 2 2 
F9 230.4 65 --- 25 15 10.6 35 15 2 2 
F10 230.4 70 --- 30 - 10.6 40 15 2 2 
F11 230.4 75 --- 25 - 10.6 40 15 2 2 
F12 230.4 80 --- 20 - 10.6 45 10 2 2 
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Drug excipient compatibility studies  
 
Fourier Transform Infrared Spectroscopy (FTIR) 
 
FTIR spectra for Quetiapine fumarate, HPMCK15 M, and optimized 
formulations were recorded using a Fourier transform Infrared 
spectrophotometer (PERKIN ELMER BX1) samples were prepared 
using KBr (spectroscopic grade) disks by means of hydraulic pellet 
press at pressure of seven to ten tons. The samples were scanned 
from 4000 to 400/cm-1 
 
Stability studies 
 
The stability studies were carried out as per ICH guidelines. The best 
formulation F12 was subjected to accelerated stability test by storing 
at 40±20C/75±5% relative humidity in an accelerated stability 
chamber (Remi, Mumbai). After specified period of time (1, 2 & 3 
months) samples were withdrawn and floating lag time, total floating 
time and in vitro dissolution studies were conducted [14]. 
 
Radiographic studies 
 
The radiographic and In-vivo bioavailability study protocol was 
approved by the Institutional Human Ethics Committee (IHEC), 
bearing No: IHEC/VGOPC/051/2015. Vaagdevi Group of Pharmacy 
Colleges, Warangal, India.  
 
Determination of In vivo gastric residence time 
 
For this study, the tablets are prepared by replacing half the amount 
of drug with barium sulfate. After overnight fasting, the volunteers 
were fed with a low calorie food. After half an hour, a barium sulfate-
labeled tablet was given to every subject with 200ml of water. The 
volunteers were asked to take 200ml water after every 1h. At 
different time intervals (0.5, 2, 4, and 6h post administration of 
tablets), the volunteers were exposed to abdominal X-ray imaging in 
standing position. The distance between the source of X-rays and 
the subject was kept constant for all images. Thus, the observation 
of the floating tablet movements could be easily noticed15. The 
mean gastric retention period was estimated. 
 
In vivo bioavailability studies Quetiapine fumarate 
In vivo study protocol16 
 
Six healthy male subjects with a mean age of 28.83±3.60 years 
(ranging from 24 to 34 years), mean weight 69.33±7.61Kg (ranging 
from 61 to 79 Kg) and a mean height of 173.17 ± 10.46cm (ranging 
from 157 to 182cm) participated in this study. Informed and signed 
consent and approval of the Human Ethical Committee were 
obtained. The volunteers were judged healthy on the basis of their 
previous medical history, physical examination and routine 
laboratory tests. None of the subjects used alcohol or tobacco. All 
subjects were free from drugs 15 days before and during the study. 
They were randomly divided into 2 groups of 6 subjects each. The 
subjects were fasted over night at least 10h prior to dose. After 
collecting the zero hour blood sample (blank). A standardized high 
fat-breakfast approximately 900KCal was given in the morning half-
an-hour before administration. Group A received Formulated 
Quetiapine fumarate and group B received commercial formulation 
was administered with 200ml of water. All the subjects were given a 
glass of water for every 2h (approximately 200 ml). Standardized 
lunch, snacks and dinner was provided to all the subjects 
respectively at 4, 8 and 12h after the administration of formulations, 
Blood samples (2ml) were collected by the intravenous route using 
heparinized disposable syringes at the following times: 0.5, 1, 1.5, 2, 
2.5, 3, 4, 6, 8, 12, 20 and 24 hrs. The blood samples were collected 
in vacutainers containing EDTA as anticoagulant and immediately 
centrifuged at 3000rpm for 15min. The separated plasma samples 
were stored at -200 C until analysed.  
 
Determination of Quetiapine fumarate in Human 
plasma by HPLC method17 
 
Determination of Quetiapine fumarate using internal standard 
lamotrogine by high performance liquid chromatography with a RP-
C18 chromatographic column, Phenomenex Kinetex (150 mm × 4.6 
mm i.d) and a mobile phase consisting of 0.1% ortho phosphoric acid 
with triethyl amine as modifier buffer: acetonitrile (50:50 % v/v) at a 
flow rate 0.6ml/min and the wavelength detection was 294 nm. 
 
Preparation of Plasma Samples for HPLC Analysis 
  
Human plasma (0.5ml) was prepared for chromatography by 
precipitating proteins with 2.5ml of ice-cold absolute ethanol for each 
0.5ml of plasma. After centrifugation the ethanol was transferred into 
a clean tube. The precipitate was resuspended with 1 ml of 
acetonitrile by vortexing for 1min. After centrifugation (5000 – 6000 
rpm for 10min), the acetonitrile was added to the ethanol and the 
organic mixture was taken to near dryness by a steam of nitrogen at 
room temperature. Samples were reconstituted in 2001 of 50% of 
acetonitrile and 50% 0.1% orthophosphoric acid was injected for 
HPLC analysis.  
 
Pharmacokinetic Analysis 
 
The pharmacokinetic parameters, peak plasma concentrations 
(Cmax) and time to reach peak concentration (tmax) were directly 
obtained from concentration time data. In the present study, AUC0-t 
refers to the AUC from 0 to 24 hrs, which was determined by linear 
trapezoidal rule and AUC0- refers to the AUC from time at zero 
hours to infinity.  
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Calculated using the formula AUC0-t + [Clast/K] where C last is the 
concentration in g/ml at the last time point and K is the elimination 
rate constant. 
Various pharmacokinetic parameters like area under the curve 
[AUC], elimination half life (t½). Volume of distribution (Vd), total 
clearance (ClT) and mean residence time for each subject using a 
non compartmental pharmacokinetic program. The pharmacokinetic 
parameters were performed by a non compartmental analysis using 
Win Nonlin 3.3® pharmacokinetic software (Pharsight Mountain 
View, CA USA). All values are expressed as the mean ±SD. 
Statistical analysis was performed with Graph Pad InStat software 
(version 3.00, Graph Pad Software, San Diego, CA, USA) using one-
way analysis of variance (ANOVA) followed by Tukey–Kramer 
multiple comparison test. Difference with p<0.05 was considered 
statistically significant. 
 
Results and discussion 
 
Twelve formulations were prepared and evaluated for in vitro 
buoyancy lag time and total floating time. The time required for the 
tablet to rise to the surface (when the tablets were placed in a beaker 
containing 0.1 N HCl) for floating was described as the buoyancy lag 
time. NaHCO3 induces CO2 generation in the presence of HCl. All 
the formulations had buoyancy lag time in the range of 32 to 45 sec. 
The total floating time was found to be more than 12 hrs, which 
indicates a stable gel layer formation by all polymers and that 
NaHCO3 remains for a longer time. The results of floating lag time 
and total floating time was depicted in Table 2 & Figure 1. 
 
Table 2: Buoyancy lag time and total floating period of Quetiapine fumarate floating tablets  
Formula code Buoyancy lag time(sec) Total floating time(hrs)  
F1          42        >12 
F2          35        >12 
F3          40        >12 
F4          42        >12 
F5          37        >12 
F6          40        >12 
F7          43        >12 
F8          37        >12 
F9          35        >12 
F10          45        >12 
F11          36        >12 
F12          32        >12 
 
 
                 At time 0                                     after 32 sec 
           Figure 1: In vitro buoyancy lag time of the optimized formulation (F12) 
 
All the formulations (F1-F12) were prepared with different grades of 
polymers like HPMC with different grades, POLYOX WSR 301 and 
a lipid excipient Gelucire 43/01. F1, F2 and F3 are having Quetiapine 
fumarate, HPMC K100M and WSR301 in different proportions 
shown the drug release was 76.3%, 80.0% and 86.5% in 12h 
respectively. The formulations F4 to F6 were developed using 
WSR301 and a combination of HPMC K15M& HPMC K100M and 
the % drug release of 77.5%, 84.2% and 91.7% respectively 
indicating comparatively better release rates than formulations F1to 
F3 (Table 3 & Figure 2). The formulation F7 was developed using 
WSR 301, Gelucire43/01 and HPMC K100M and the %drug release 
was 93%. The formulations F8 and F9 were developed using WSR 
301, Gelucire 43/01 and HPMC K15M and the %drug release was 
found to be 95.6 % and 97.0% in 12h. The formulations F10, F11 
and F12 were developed using WSR 301 and HPMC K15M and the 
% drug release was found to be 94.7 %, 96.8 % and 98.6% in 12hrs 
respectively. The results are summarized in Table 4& Figure 3.  
Formulation F12 selected as optimized formulation based on the 
better drug release, lag time and total floating time.  
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Table 3: Cumulative percent drug release of formulations F1-F6 
Time (h) F1 F2 F3 F4 F5 F6 
0 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
1 11.3±0.34 12.6±0.55 13.0±0.26 11.7±0.14 12.9±0.43 13.1±0.43 
2 17.7±0.14 19.0±0.28 24.6±0.7 18.1±0.1 23.4±0.34 22.0±0.52 
4 28.3±0.43 33.2±0.5 38.6±0.52 28.7±0.43 37.6±0.34 40.0±0.5 
6 40.8±0.52 43.6±0.43 48.0±0.52 41.2±0.4 46.0±0.52 52.2±0.52 
8 52.3±0.21 53.9±0.26 61.7±0.14 53.6±0.52 59.7±0.14 69.9±0.43 
10 60.5±0.4 65.4±0.34 72.6±0.34 62.0±0.52 72.3±0.2 79.8±0.26 
12 76.3±0.3 80.0±0.52 86.5±0.1 77.5±0.34 84.2±0.43 91.7±0.14 
 
Figure 2: Drug release profile from formulations F1, F2, F3, F4, F5 and F6 
 
Table 4: Cumulative percent drug release of formulations F7-F12 
Time (h) F7 F8 F9 F10 F11 F12 innovator 
0 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
1 13.0±0.43 13.4±0.34 13.6±0.2 13.6±0.26 13.8±0.52 14.0±0.34 94.9±0.45 
2 22.6±0.52 23.0±0.43 23.9±0.1 22.0±0.52 23.4±0.34 24.2±0.60 - 
4 40.5±0.5 41.1±0.43 42.0±0.52 41.0±0.14 41.2±0.26 42.6±0.1 - 
6 51.0±0.52 51.8±0.52 53.1±0.43 50.2±0.52 52.6±0.43 54.0±0.43 - 
8 70.2±0.43 71.0±0.28 73.2±0.26 70.7±0.14 72.2±0.14 73.5±0.7 - 
10 81.2±0.26 85.5±0.1 88.5±0.43 81.8±0.43 86.5±0.1 89.2±0.52 - 
12 93.0±0.14 95.6±0.26 97.0±0.52 94.7±0.14 96.8±0.26 98.6±0.69 - 
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Figure 3: Drug release profile from formulations F7-F12 and innovator 
 
 
Mathematical modeling of floating tablets 
 
To explore the mechanism of drug release from QF floating tablets, 
various kinetic models like zero order, first order, Higuchi and 
Korsmeyer-Peppas equations were applied to the different 
formulations. The release order kinetics of optimized formulation 
(F12) was shown in Table 5. From the above results it is apparent 
that the regression coefficient value closer to unity in case of zero 
order plot i.e. 0.979 indicates that the drug release follows a zero 
order mechanism. This data indicates a lesser amount of linearity 
when plotted by the first order equation. Hence it can be concluded 
that the major mechanism of drug release follows zero order kinetics. 
Further, the translation of the data from the dissolution studies 
suggested possibility of understanding the mechanism of drug 
release by configuring the data into various mathematical modeling 
such as Higuchi and Korsmeyer-Peppas plots. The mass transfer 
with respect to square root of time has been plotted, revealed a linear 
graph with regression value close to one i.e. 0.986 stating that the 
release from the matrix was through diffusion. Further the n value 
obtained from the Korsmeyer plots i.e. 0.790 suggest that the drug 
release from floating tablet was anomalous non-fickian diffusion. 
 
Table 5: Release order kinetics of optimized formulation (F12) 
Formula code 
Zero order First order Higuchi Korsmeyer-Peppas 
R2 
 
  K 
R2 
 
K 
R2 
 
K 
R2 
 
N 
F12 0.979 8.821 0.832 0.141 0.986 35.06 0.998 0.790 
 
 
Drug -excipient compatibility studies 
 
Figure 4: FTIR spectrum Quetiapine fumarate 
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Figure 5: FTIR spectrum of optimized formulation (F12) 
 
The FT-IR spectra of pure drug QF (Figure 4) and optimized 
formulation F12 (Figure 5) were found to be identical. The FTIR 
spectra of the optimized formulation displayed the characteristic 
peaks of both drug and polymers. Overall there was no alteration in 
the characteristic peaks of Quetiapine fumarate suggesting that 
there was no interaction between the drug and polymer. 
 
Stability studies 
 
The stability of optimized formulation (F12) of quetiapine fumarate 
floating tablets were tested for stability at 40°C/75%RH in properly 
closed HDPE bottles along with 1 gm desiccant for 3 months. The 
quetiapine fumarate release rate (Table 6) from the floating tablets 
(F22) showed no significant change during storage for 3 months, 
there is no significant change in floating lag time, total floating time 
and also in vitro drug release profile. The formulation stored in both 
conditions for 3 months floated on the surface of the media (0.1N 
HCl) for 12h.  
Table 6: Physico-chemical characteristics of optimized formulation (F12) stored at 40 ±2ºC /75 ±5%RH for 90 days 
Retest Time For F12 
Floating lag time(sec)* Total Floating time (h)* In-vitro drug release 
profile (%)* 
0 days 32±2.6 >12hrs 98.6±0.69 
30 days 33±2.4 >12hrs 98.2±0.25 
60 days 33±1.2 >12hrs 97.6±0.83 
90 days 34±3.5 >12hrs 97.0±0.19 
*Mean ± S.D (n=3) 
 
Intragastric behavior of Quetiapine fumarate floating 
tablets 
 
The radiographic images were taken at different periods post 
administration of the barium sulfate-loaded tablet in three human 
volunteers (Figure 6). It is clear that the tablet appears more or less 
at the same position for the initial 4h. This could be related to its 
floating ability. Later on, the tablet was slightly moved downwards, 
yet, remained within the stomach till the end of 6h. The increased 
gastric residence time favours increase in the bioavailability of drugs. 
 
 
                    0.5 hours                              2 hours        
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                         4 hours                         6 hours   
Figure 6: Radiographic images of optimized Quetiapine fumarate floating tablet (F12) in the stomach at different time 
intervals 
 
 
 
 
In vivo bioavailability studies: 
 
 
Figure 7: Plasma concentrations at different time intervals for Quetiapine fumarate optimized formulation and Marketed Product 
 
Table 7: Comparison of pharmacokinetic parameters of Quetiapine fumarate optimized formulation and Marketed Product 
Parameters 
Quetiapine fumarate 
Optimized formulation  (F12) 
Marketed Product 
Cmax(ng/ml) 454±30.21 385±91.25 
AUC0-t(ng. h/ml) 3176±56.44 2597±44.26 
AUC0-∞ (ng. h/ml) 3325±28.14 2826±38.12 
Tmax (h) 4.00±1.23 3.50±0.24 
t1/2 (h) 9.053 ± 0.519 8.164 ± 0.01 
Kel (h-1) 0.051 ± 0.016 0.084 ±  0.018 
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Bioavailability parameters 
 
Mean plasma concentration profiles of prepared Quetiapine 
fumarate optimized formulation and marketed product are presented 
in Figure 7. Quetiapine fumarate optimized formulation exhibited as 
sustained release in vivo when compared with marketed tablet. All 
the pharmacokinetics parameters displayed in Table 7. In this study 
in human subjects, prolonged drug absorption was achieved with the 
test formulation. The average peak concentration of the test 
formulation was significantly higher than that of the reference 
(454±30.21ng/ml for the test formulation versus 385±91.25ng/ml for 
the reference). In order to estimate the amount of drug absorbed 
from the test formulation, the relative bioavailability was calculated 
from the AUC of the reference and test formulations (2826±38.12ng. 
h/ml for the reference product versus 3325±28.14ng. h/ml for the test 
formulation). The results indicated that the test formulation could 
increase the bioavailability of Quetiapine fumarate in humans 
effectively. In this study, the Quetiapine fumarate floating tablet 
produce higher bioavailability than that of a marketed product, this 
overall increase in bioavailability and increased gastric residence 
time, caused by flotation of dosage form in the stomach. 
 
Summary and conclusion 
 
Present study aims in design of sustained release floating 
formulations of Quetiapine fumarate using different polymers like 
Gelucire 43/01, POLYOX WSR 301, HPMC K15M and HPMC 
K100M etc polymers to control the drug release and a lipid excipient 
to decrease the gastric irritation and to enhance the penetration of 
drug. Based on the evaluation parameters for F12 was found to be 
optimized formulation upon its floating lag time, buoyancy period and 
in vitro drug release was better than other formulations. The kinetic 
data revealed that the regression coefficient value of optimized 
formulation F12 closer to unity in case of zero order plot i.e. 0.979 
indicates that the drug release follows a zero order mechanism. The 
mass transfer with respect to square root of time has been plotted, 
revealed a linear graph with regression value close to one i.e. 0.986 
stating that the release from the matrix was through diffusion. Further 
the n value obtained from the Korsmeyer plots i.e. 0.790 suggest that 
the drug release from floating tablet was anomalous non fickian 
diffusion. The comparison plot of the In vitro drug release profiles of 
optimized formulation and innovator indicating the better drug 
release in F12 than innovator. The drug excipient compatibility 
studies were carried out to rule out any interactions between the drug 
and the polymers/excipients by FTIR and differential scanning 
calorimetric analysis.  From the above results can conclude that the 
drug release from the optimized formulation F12 was in sustained 
manner for 12h by increasing the gastric residence time. The best 
formulation (F12) was selected based on in vitro characteristics and 
was used in vivo radiographic studies by incorporating BaSO4. 
These studies revealed that the tablets remained in the stomach for 
6h in fasting human volunteers and indicated that gastric retention 
time was increased by the floating principle, which was considered 
desirable for the absorption window drugs. Studies to evaluate the 
pharmacokinetics in vivo showed better bioavailability, area under 
the concentration–time curve, elimination rate constant and half-life 
than marketed product. 
 
  
  
 
 
References 
 
 
[1]. Rouge N, Buri P, Doelker E. Drug 
absorption sites in the gastrointestinal 
tract and dosage forms for site specific 
delivery. Int J Pharm. 1996; 136: 117-
139. 
[2]. Singh BN, Kim KH. Floating drug 
delivery systems: an approach to oral 
controlled drug delivery via gastric 
retention. J. Control Release. 2000; 63: 
235-239.  
[3]. Harshal P, Gahiwade V, Manohar P, 
Bharat Tekade W, Vinod Thakare M, 
Patil V R. formulation and in-vitro 
evaluation of trifluoperazine 
hydrochloride bilayer floating tablet. Int 
J of Phar Bio Sic. 2012; 2 (1): 166-172. 
[4]. Tadros MI. Controlled-release 
effervescent floating matrix tablets of 
ciprofloxacin hydrochloride: 
development, optimization and in vitro-
in vivo evaluation in healthy human 
volunteers. Eur J Pharm and Biopharm. 
2010; 74: 332–33. 
[5]. Sarfaraz Md, Keerthi Chandra Reddy P, 
Udupi R H, Doddayya H. Formulation 
and In-Vitro Evaluation of Bilayer 
Floating tablets of Tramadol 
Hydrochloride. Int j of drug dev and res. 
2012; 4 (3): 335-347.  
[6]. Rajani S, Ranendra Saha T N. In vitro 
and in vivo evaluation of gastroretentive 
floating drug delivery system of 
ofloxacin. Asian J of Pharma Sci. 2013; 
8 (3): 191-198. 
[7]. Mohan G, Ramesh B, Kishan V. 
Development of sustained release 
floating drug delivery system for 
norfloxacin: In vitro and in vivo 
evaluation. PDA J of Pharma sci and 
tech. 2011; 65: 198-206. 
[8]. Streubel A, Siepmann J, Bodmeier R. 
Floating matrix tablets based on low 
density foam powder: effects of 
formulation and processing parameters 
on drug release. Eur. J. Pharm. Sci. 
2003; 18 (1): 37– 45.  
[9]. Nirav Sheth S. Formulation and 
evaluation of floating drug delivery 
Babu et al, International Journal of Drug Delivery 8 (1) 12-22 [2016] 
 
 
  
PAGE | 22 | 
 
 
system Int of Pharma and Bio Sci. 2011; 
2 (1): 571-80. 
[10]. Mullen J, Jibson MD, Sweitzer D. A 
comparison of the relative safety, 
efficacy, and tolerability of quetiapine 
and risperidone in outpatients with 
schizophrenia and other psychotic 
disorders: the quetiapine experience 
with safety and tolerability (QUEST) 
study. Clin Ther. 2001; 23: 1839-54. 
[11]. Tadros M. Eur J of Pharma and 
Biopharma. Controlled-release 
effervescent floating matrix tablets of 
ciprofloxacin hydrochloride: 
Development, optimization and in vitro-
in vivo evaluation in healthy human 
volunteers.2010; 74: 332–339. 
[12]. Higuchi T, Mechanism of sustained 
action medication theoretical analysis of 
rate of release of solid drugs dispersed 
in solid matrices. J Pharm Sci, 1961, 50, 
874-875. 
[13]. Siepmann J, Peppas N.A. Modeling of 
drug release from delivery systems 
based on hydroxypropyl methylcellulose 
(HPMC). Adv Drug Delivery Reviews. 
2001; 48: 139-157. 
[14]. Garg R, Gupta GD. Progress in 
Controlled Gastroretentive Delivery 
Systems. Trop J of Pharm Res. 2008; 7 
(3): 1055-1066. 
[15]. Anand Patel. Development and In Vivo 
Floating Behavior of Verapamil HCl 
Intragastric Floating Tablets. AAPS 
PharmSciTech. 2009; 10(1): 310-315. 
[16]. Prasanna Kumari J, Ramarao T, 
Jayaveera K N, Bhikshapathi D V R N, 
Madhusudan Rao Y. Design and In vivo 
evaluation of Metoprolol Tartrate bilayer 
floating tablets in healthy human 
volunteers. Int J of Drug Delivery. 2014; 
6: 14-23.  
[17]. Kiran B. V, Sreenivas Rao 
B, Somshankar D. Validation of 
Quetiapine Fumarate in Pharmaceutical 
Dosage by Reverse-Phase HPLC with 
Internal Standard Method, J of 
Chemistry. 2013; Article ID 578537.
 
 
